Notice of Annual General Meeting

RNS Number : 2366M

Genflow Biosciences PLC

20 May 2022

 

PRESS RELEASE

20 May 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

Notice of Annual General Meeting

Genflow (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age, is pleased to announce that it will hold its Annual General Meeting ("AGM") at 09:00am on Tuesday 14^th June 2022 at the offices of Westend Corporate LLP, 48 Warwick Street, London, W1B 5AW.

The Notice of the AGM ("Notice") and 2022 Form of Proxy are now available on the Company website, www.genflowbio.com , and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.

As announced on 29 April 2022, the Company's Annual Report and Accounts for the year ended 31 December 2021 is also available on the website and has, where applicable, also been posted to shareholders.

For further information please contact:

Genflow Biosciences Plc
Dr Eric Leire Chief Executive	via Tancredi [phone]
Clear Capital Markets Ltd
Corporate Broker  Jonathan Critchley Keith Swann	[phone] [phone]
Tancredi Intelligent Communication Media Relations
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio	[phone] [phone] [phone] [e-mail]

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

-Ends-

 

END

 

 

NOAURRNRUOUVURR